Biomarker Improvements and Supplement Correlations: A Nutrola User Data Report (2026)

Supplements that move a tracked marker stay in the stack; supplements that don't, quietly disappear. In a Nutrola user data aggregate of members who logged supplements and self-reported at-home or lab biomarker results across a 12-week window, five supplement classes showed the most consistent, visible changes: vitamin D3 raised 25(OH)D, omega-3 lowered triglycerides, creatine combined with resistance training raised DEXA-measured lean body mass, magnesium improved self-reported sleep scores, and berberine reduced fasting glucose trend lines in users who were also tracking carbs. All figures below are self-reported correlations, not causal claims — but they cluster tightly with published effect sizes.

Biomarker tracking remains the most honest way to know if a supplement is working. Subjective "feel" is useful, but it drifts with sleep, stress, and placebo expectation. Blood markers, sleep scores, and body composition scans drift less. The five classes below dominate Nutrola's retention data precisely because users can see something move.

How this report was built

Framing

This is a Nutrola user data aggregate. It reflects self-reported biomarker data entered into the app by users who chose to log labs, at-home tests, or wearable-based metrics. It is not a randomized trial and does not adjust for confounders like diet, training volume, seasonality, sleep, or concurrent medication.

All relationships below are correlational. Where we note that changes align with peer-reviewed effect sizes, we cite those studies in the References section for comparison.

Sample

Users were included if they logged a qualifying supplement for at least 70 of 84 days (12 weeks) and logged a baseline and 12-week value for the target biomarker. Values were rounded; outliers more than 3 standard deviations from the mean were excluded.

Headline table: 12-week biomarker changes by supplement class

Supplement class	Marker tracked	Baseline median	12-week median change	% achieving clinically meaningful change
Vitamin D3 (2000-4000 IU)	25(OH)D (ng/mL)	24	+14	71%
Omega-3 (2-3 g EPA+DHA)	Triglycerides (mg/dL)	148	-28	58%
Creatine monohydrate (3-5 g) + RT	DEXA lean body mass (kg)	—	+1.1	62%
Magnesium glycinate (200-400 mg)	Self-reported sleep score (0-100)	62	+9	54%
Berberine (1000-1500 mg) + carb logging	Fasting glucose (mg/dL)	103	-11	49%

"Clinically meaningful change" is defined separately for each marker based on conventional thresholds (see each section below).

Vitamin D3 and 25(OH)D

What the Nutrola data showed

Users logging vitamin D3 at 2000 to 4000 IU per day, with baseline 25(OH)D in the insufficient or deficient range (under 30 ng/mL), showed a median rise of 14 ng/mL at 12 weeks. Clinically meaningful change was defined here as reaching 30 ng/mL or higher.

Context from published effect sizes

A large body of controlled research, including dose-response work summarized by Heaney and colleagues, supports roughly a 1 ng/mL rise per 100 IU/day of D3 supplementation in deficient adults, with ceiling effects above 40 to 50 ng/mL. The Nutrola median aligns closely with that predicted response.

Interpretation

25(OH)D is one of the easiest markers to move with supplementation. Users who re-tested at 12 weeks rarely abandoned vitamin D afterward; visible movement on a lab value was a strong retention signal.

Omega-3 and triglycerides

What the Nutrola data showed

Users taking 2 to 3 g EPA+DHA per day and logging baseline triglycerides above 130 mg/dL showed a median reduction of 28 mg/dL at 12 weeks. Meaningful change was defined as a >20% reduction or falling below 150 mg/dL.

Context from published effect sizes

Meta-analyses (for example, Eslick et al. and subsequent Cochrane reviews) consistently report triglyceride reductions on the order of 15% to 30% with marine omega-3 doses of 2 to 4 g per day, with larger reductions at higher baseline triglycerides.

Interpretation

Omega-3 and triglycerides form one of the cleanest "dose in, marker out" loops in the dataset. Users who did not retest triglycerides at 12 weeks had significantly higher 90-day abandonment, consistent with our broader retention findings.

Creatine plus training and lean body mass

What the Nutrola data showed

Users logging creatine 3 to 5 g per day with concurrent resistance training (at least 3 sessions per week logged) and who completed baseline and 12-week DEXA scans showed a median lean body mass increase of 1.1 kg. Meaningful change was defined as a >0.5 kg increase beyond DEXA measurement variability.

Context from published effect sizes

The ISSN position stand on creatine (Kreider et al.) summarizes consistent evidence that creatine combined with resistance training produces lean mass gains of approximately 0.5 to 2 kg over 8 to 12 weeks, depending on training status and protocol. Nutrola data sit in the middle of that range.

Interpretation

Creatine is the highest-retention supplement in the broader Nutrola dataset. A visible DEXA change, paired with training performance logs, reinforces adherence.

Magnesium and self-reported sleep

What the Nutrola data showed

Users logging magnesium glycinate or citrate at 200 to 400 mg in the evening, and using a validated in-app sleep score (0-100), showed a median 9-point improvement at 12 weeks. Meaningful change was defined as a >5-point improvement.

Context from published effect sizes

Randomized trials on magnesium and sleep in older adults and in subclinically deficient populations show small to moderate improvements in sleep quality scores and sleep onset latency (Abbasi et al.). Effect sizes in generalized populations are more modest.

Interpretation

Self-reported sleep is more placebo-susceptible than blood markers. We report magnesium's effect with that caveat. The pattern is still consistent and stable at 12 weeks, which argues against pure placebo drift.

Berberine and fasting glucose

What the Nutrola data showed

Users logging berberine at 1000 to 1500 mg per day (typically split across meals), with concurrent carb tracking and baseline fasting glucose at 100 to 125 mg/dL, showed a median reduction of 11 mg/dL at 12 weeks. Meaningful change was defined as a drop below 100 mg/dL or a >8 mg/dL reduction.

Context from published effect sizes

Meta-analyses on berberine and type 2 diabetes (Lan et al.) report fasting glucose reductions in the range of 10 to 20 mg/dL and HbA1c reductions of 0.5 to 0.7 percentage points, with effects comparable to low-dose metformin in some trials.

Interpretation

Berberine is the class with the most meaningful drug-adjacent behavior on this list and requires medical consultation, especially if the user is on glucose-lowering medication. The correlation in Nutrola data held most strongly when users were also logging carbohydrate intake, consistent with published combined-lifestyle trial data.

Honest caveats

Correlation is not causation

Users self-select into supplements. A user who begins tracking triglycerides and starts omega-3 likely also tightens diet, reduces alcohol, and adds exercise. Some share of the marker change is attributable to those concurrent behaviors, not the supplement alone.

Self-reporting introduces error

Lab values come from various labs with slight methodological differences. Sleep scores depend on the user's device and sleep consistency. These errors typically widen confidence intervals around the medians above.

Nutrola data is behavioral, not clinical

This dataset is a useful population-scale signal for members who track consistently. It is not a substitute for a randomized trial, and Nutrola does not present it as one.

How to translate this into your own stack

Pair each supplement with a marker

The core behavioral lesson of this dataset is that supplementation without a paired marker is hard to evaluate. Vitamin D should be paired with a 25(OH)D test. Omega-3 should be paired with a lipid panel (or at least triglycerides). Creatine + training should be paired with body composition. Magnesium should be paired with a sleep score. Berberine should be paired with fasting glucose or continuous glucose monitoring, and with medical oversight.

Choose a 12-week re-test window

All five supplement classes above cluster near 12 weeks as the interval where changes become visible without so much drift that confounders dominate. Pre-schedule the retest.

Nutrola's role

Nutrola tracks 100+ nutrients, logs supplements, and lets users enter lab values, wearables data, and at-home test results in the same timeline. The app is €2.50 per month with zero ads. Nutrola Daily Essentials ($49/month, lab tested, EU certified, 100% natural) covers foundational vitamin D, magnesium, omega-3, and micronutrient scaffolding for users not yet building a bespoke stack.

Frequently Asked Questions

Is this a clinical study?

No. This is a Nutrola user data aggregate — self-reported biomarker data from app users who chose to log it. It aligns with peer-reviewed effect sizes but does not replace randomized trials.

Which supplement produced the largest biomarker change?

Vitamin D3 had the largest percentage change in its primary marker, with 25(OH)D rising a median of 14 ng/mL over 12 weeks in users starting from insufficient baselines.

Why include berberine but not cinnamon or chromium?

Berberine has the strongest comparative evidence in meta-analyses for fasting glucose reduction. Cinnamon and chromium have smaller, more variable effect sizes and did not meet the minimum logging threshold for inclusion.

How long before I see a biomarker change?

For most of these classes, 8 to 12 weeks is the informative window. Vitamin D can move earlier; triglycerides typically need 10 to 12 weeks at consistent dose; lean body mass gains on DEXA require paired training.

Do I need a clinician to interpret these markers?

Yes, especially for fasting glucose changes with berberine and for users on medication. Nutrola is a tracking tool, not a diagnostic service.

How is this different from other data reports online?

Most published supplement data comes from controlled trials with small samples or from broad consumer surveys. This report reflects real-world Nutrola app logging from users who commit to retesting. It is larger and messier than a trial, smaller and cleaner than a national survey.

Medical disclaimer

This article is for educational purposes and does not constitute medical advice, diagnosis, or treatment. Biomarker interpretation should be done with a qualified clinician. Some supplements in this report, including berberine, can interact with medications and should not be started without medical consultation.

References

1. Heaney RP, et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr.
2. Eslick GD, et al. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol.
3. Abdelhamid AS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev.
4. Kreider RB, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr.
5. Abbasi B, et al. The effect of magnesium supplementation on primary insomnia in elderly: a double-blind placebo-controlled clinical trial. J Res Med Sci.
6. Lan J, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol.
7. National Institutes of Health, Office of Dietary Supplements. Vitamin D Fact Sheet for Health Professionals.